Effects of respiratory and metabolic alkalosis and acidosis on pipecuronium neuromuscular block

[Effects of changes in ion concentrations, osmolarity, and pH on recovery from atracurium- or vecuronium-induced neuromuscular blockade]

OBJECTIVES

To determine changes in sodium, potassium, calcium, magnesium and chloride ion concentrations in blood, osmolarity, and pH during surgery, and to assess the influence of such changes on atracurium- or vecuronium-induced neuromuscular blockade under inhaled or intravenous anesthesia.

MATERIAL AND METHODS

Prospective study randomizing 119 ASA 1-2 patients; 52.1% of the patients received atracurium (26.8%, with isoflurane; 25.2%, with propofol) and 47.9% received vecuronium (23.5%, with isoflurane; 24.3%, with propofol). The neuromuscular blockade was confirmed by electromyography of the adductor pollicis muscle (stimuli delivered to the cubital nerve). Two venous blood samples were extracted to measure ureic nitrogen, creatinine, glucose, ion concentrations (sodium, chloride, potassium, calcium, and magnesium), and osmolarity. Arterial blood gases and pH were also assessed. The first blood sample was extracted on inserting the venous catheter and the second on recovery of 25% of the first train-of-four twitch.

RESULTS

The onset and duration of action for equipotent doses of atracurium and vecuronium were similar. Likewise, recovery was also similar. Plasma chloride ion and glucose levels tended to rise during surgery, while sodium, potassium and magnesium ion concentrations fell. Both total and effective plasma osmolarities also decreased. Fluid replacement therapy during surgery was at least partly responsible for these changes. Low calcium and magnesium concentrations and alkalosis prolonged some phases of atracurium recovery, while low sodium levels shortened the duration of some atracurium-induced blockade recovery phases. The effect of changes in chloride ion concentrations on recovery was variable. High chloride, low calcium, and especially low sodium ion concentrations shortened some phases of the vecuronium-induced blockade, while alkalosis prolonged its duration.

CONCLUSIONS

Changes in electrolyte concentrations and pH as a result of standard fluid replacement therapy are moderate, well tolerated, and do not exercise a strong effect on the behavior of the neuromuscular blockade.

Clinical limitations of acetylcholinesterase antagonists

Administration of a nondepolarizing neuromuscular blocking drug (muscle relaxant) is a standard practice in many anesthetic scenarios. These muscle relaxants work by competitive antagonism of the neurotransmitter acetylcholine at nicotinic cholinergic receptors within the neuromuscular junction of skeletal muscle (Martyn et al; Neuromuscular physiology and pharmacology, anesthesia. Edited by RD Miller, Philadelphia, Churchill Livingstone, 2000). At the conclusion of the procedure for which the muscle relaxant was administrated, there will be a greater or lesser degree of residual muscle weakness. It is usually necessary to pharmacologically reverse this residual weakness to restore full function to the patient's muscles. Indeed, failure to reverse neuromuscular block is associated with increased perioperative morbidity and mortality (Arbous et al; Impact of anesthesia management characteristics on severe morbidity and mortality. Anesthesiology 2005;102:257-268; quiz 491-2). Pharmacologic reversal currently relies on the administration of an anticholinesterase drug, which decreases the metabolism of acetylcholine at the neuromuscular junction and allows its concentration to increase and hopefully overcome the effect of the muscle relaxant. This approach to reversal has significant limitations; the mechanism of reversal is indirect, the efficacy is limited and unpredictable, and undesirable autonomic responses occur. This review will address these limitations.

Newer neuromuscular blocking drugs. An overview of their clinical pharmacology and therapeutic use

Four new nondepolarising muscle relaxants, pipecuronium bromide, doxacurium chloride, mivacurium chloride and Org 9426 (rocuronium) offer alternatives to the established agents atracurium besilate and vecuronium bromide. Pipecuronium and Org 9426 are steroidal compounds, the latter being a monoquaternary agent, whereas doxacurium and mivacurium are bisquaternary benzylisoquinolinium compounds. Pipecuronium and doxacurium have a relatively slow onset and a long duration of action. Pipecuronium produces maximum block in 3 to 6 min when given in a dose of 45 to 80 micrograms/kg, and a duration of clinical relaxation of between 40 and 110 min. Doxacurium is more potent, but is the least rapid and the longest acting relaxant currently available. When administered in doses of 37 to 80 micrograms/kg, it produces maximum block within 3.5 to 10 min, with a duration of clinical relaxation of 77 to 164 min. The advantage of both pipecuronium and doxacurium is their cardiovascular stability. Both agents are primarily eliminated via the kidneys and both have now been licensed for use in the US. Mivacurium is a muscle relaxant with a short duration of action. When administered in doses of 0.1 to 0.25 mg/kg it produces maximum block in 2 to 4 min, but the duration of clinical relaxation is less than 20 min. Higher doses which could induce a faster neuromuscular block are unfortunately associated with some histamine liberation. The drug is metabolised by plasma cholinesterase. Mivacurium has also been licensed for use in the US. Org 9426 is an agent with a rapid onset but an intermediate duration of action. A dose of 0.5 to 0.6 mg/kg induces maximum block in about 1.5 min and has a duration of clinical relaxation of about 30 min. The rapid onset of effect could be useful for early intubation as an alternative to suxamethonium chloride. However, much more clinical experience is needed with this agent, particularly with regard to duration of action of larger doses and occurrence of side effects. The drug is mainly eliminated via the liver.